National kidney disease education program

Journal of the American Society of Nephrology

Volumn 14, Issue SUPPL. 2, 2003, Pages

  Hostetter, Thomas H ^a,b   Lising, Mimi ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUING EDUCATION; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIET THERAPY; DISEASE COURSE; DRUG EFFICACY; EDUCATION PROGRAM; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH EDUCATION; HEALTH PROMOTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PATIENT COUNSELING; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN RESTRICTION; UNITED STATES;

EID: 0038544483     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. US Renal Data System: USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, NIH, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
2. http://www.nci.nih.gov/cancerinfo/index.html
3. Fodor JG, Adamo KB: Prevention of type 2 diabetes mellitus by changes in lifestyle. N Engl J Med 345: 696-697, 2001
4. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342: 381-389, 2000
5. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352: 837-853, 1998
6. Hostetter TH: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 345: 910-912, 2001
7. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassmann J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S: African American Study of Kidney Disease and Hypertension (AASK) Study Group: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285: 2719-2728, 2001
8. Kasiske BL, Lakatua JD, Ma JZ, Louis TA: A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 31: 954-961, 1998
9. McClellan WM, Knight DF, Karp H, Brown WW: Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: Important differences between practice and published guidelines. Am J Kidney Dis 29: 368-375, 1997
10. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Bethesda, MD, NIH Publication No. 98-4080, National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program, 1997